Three Quick Facts: Hollywood Bowl, Oncimmune and Remote Monitored Systems

14th December 2020
Tony Cross
Three Quick Facts
Hollywood Bowl, Oncimmune Holdings, Remote Monitored Systems

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

Hollywood Bowl

Full year numbers are out from Hollywood Bowl [LON:BOWL] this morning, with the company understandably having struggled in the wake of COVID-19 restrictions. This covers the period to September 30th and revenues are down almost 40%, although investors may be able to take some solace from the fact that on a like-for-like basis, the number shows some very modest growth. Clearly that’s a subjective view, but keeping with the glass-half-full view, the company also managed to maintain profitability. With 60% of facilities having reopened after the last lockdown, the company sees itself as operating in an agile manner and is optimistic that COVID secure measures plus an ongoing capex commitment will allow them to trade through this.

Oncimmune

Oncimmune [LON:ONC], the AIM-listed global immunodiagnostics company, has this morning announced two deals with the NHS, using its kit to diagnose lung cancers. The company has seen its stock finding favour over the summer off the back of its work in battling COVID, so this news is a timely reminder of the fact this company is working on more than just one project.

Subscribe for more stories like this, 8am weekdays - for free!
Your email address

Remote Monitored Systems

There’s a very short update out from Remote Monitored Systems [LON:RMS] this morning regarding progress with its recently acquired Pharm 2 Farm business. The company’s new production line for antiviral materials has apparently passed acceptance testing – delays here in recent months had dampened shareholder optimism, so whether today’s news is sufficient to provide reassurance will be interesting to watch.

Find out how our picks got on in November

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.